Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001127602-20-019791)

Filing Details

Accession Number:
0001127602-20-019791
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-16 18:19:02
Reporting Period:
2020-06-12
Accepted Time:
2020-06-16 18:19:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
313143 Haemonetics Corp HAE Surgical & Medical Instruments & Apparatus (3841) 042882273
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1699629 L Michelle Basil 125 Summer Street
Boston MA 02110		 Evp And General Counsel No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-12 24,014 $0.00 40,390 No 4 A Direct
Common Stock Disposition 2020-06-12 203 $89.29 40,187 No 4 S Direct
Common Stock Disposition 2020-06-15 10,578 $87.71 29,609 No 4 S Direct
Common Stock Disposition 2020-06-16 5,175 $90.32 24,434 No 4 S Direct
Common Stock Disposition 2020-06-16 6,961 $91.34 17,473 No 4 S Direct
Common Stock Disposition 2020-06-16 1,300 $92.14 16,173 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on June 6, 2017, based on the issuer's total shareholder return relative to that of the companies comprising a blended index of the S&P MidCap 400 and S&P SmallCap 600 for the performance period from June 6, 2017 to June 5, 2020, as certified by the Compensation Committee of the Board of Directors on June 12, 2020.
  2. This number includes unvested restricted stock units ("RSUs") previously reported.
  3. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the PSUs reported above on June 12, 2020. This sale is mandated by the Issuer's election under its 2005 Long-Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  5. Transaction pursuant to an existing 10b5-1 trading plan.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.93 to $90.93, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (6) through (8) to this Form 4
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.95 to $91.93, inclusive.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.00 to $92.24, inclusive.